Related Experiment Video
Updated: Jul 4, 2026
Sample Preparation for Probe Electrospray Ionization Mass Spectrometry
Published on: February 19, 2020
Senescence marker protein 30 in acute liver failure: validation of a mass spectrometry proteomics assay
Sa Lv1, Jiang-hua Wang, Feng Liu
1Peking University People's Hospital, Peking University Hepatology Institute, Beijing 100044, PR China. vsa@sina.com
Background:
Our previous proteomic study showed that the senescence marker protein (SMP30) is selectively present in the plasma of a murine model of acute liver failure (ALF). The aim of this study was to validate this SMP30 expression in the plasma and liver tissues of mice and humans with ALF.
Methods:
After the proteomic analysis of plasma from a murine model of D-galactosamine/lipopolysaccharide (GalN/LPS)-induced ALF by two-dimensional electrophoresis (2-DE) and mass spectrometry, the expression levels of SMP30 in the plasma and liver tissues were validated by western blot and RT-PCR analyses. These results were then confirmed in plasma samples from humans.
Results:
These data validate the results of 2-DE, and western blot showed that SMP30 protein levels were only elevated in the plasma of ALF mice. Further analysis revealed that GalN/LPS induced the downregulation of SMP30 protein levels in liver tissues (by approximately 25% and 16% in the GalN/LPS-treated mice and in the treated mice that survived, respectively; P < 0.01). Hepatic SMP30 mRNA levels decreased by about 90% only in the mice that survived the GalN/LPS treatment. Importantly, plasma obtained from patients with ALF also contained higher levels of SMP30, about (3.65 +/- 0.34) times those observed in healthy volunteers.
Conclusion:
This study shows that SMP30 is not only a potential biomarker for the diagnosis and even prognosis of ALF. It also plays a very important role in a self-protective mechanism in survival and participates in the pathophysiological processes of ALF.
Insights
Senescence marker protein 30 (SMP30) is elevated in the plasma of acute liver failure (ALF) patients and mice. This protein may serve as a diagnostic and prognostic biomarker for ALF, playing a role in survival mechanisms.
Area of Science:
- Biochemistry
- Hepatology
- Proteomics
Background:
- Previous proteomic analysis identified senescence marker protein (SMP30) in the plasma of a murine model of acute liver failure (ALF).
- This finding suggested SMP30's potential role in ALF pathogenesis.
Purpose of the Study:
- To validate the expression of SMP30 in plasma and liver tissues of both mice and humans with ALF.
- To investigate SMP30's diagnostic and prognostic potential in ALF.
Main Methods:
- Utilized two-dimensional electrophoresis (2-DE) and mass spectrometry for initial proteomic analysis.
- Validated SMP30 expression using Western blot and RT-PCR in murine models.
- Confirmed findings in human plasma samples from ALF patients.
Main Results:
- SMP30 protein levels were significantly elevated in the plasma of ALF mice and human patients compared to controls.
- GalN/LPS treatment led to downregulation of SMP30 protein and mRNA in liver tissues.
- Plasma SMP30 levels in ALF patients were approximately 3.65 times higher than in healthy volunteers.
Conclusions:
- SMP30 is a potential biomarker for diagnosing and predicting the prognosis of ALF.
- SMP30 plays a role in the self-protective mechanisms during ALF survival.
- The study highlights SMP30's involvement in the pathophysiological processes of ALF.
